Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →This dataset tracks patent activity in caprolactam production and nylon 6 intermediate synthesis, built around the ammoximation route to cyclohexanone oxime, the Beckmann rearrangement that converts oxime to lactam, and the ammonium sulfate byproduct problem that has shaped process design since the hydroxylamine route era. The scope is defined by IPC classes C07D201, C07C249 and C08G69, filtered to records that name these process steps directly rather than downstream polymer claims.
691 records fall within scope from 2015 through the 2026 data cut-off. Publication lags filing by roughly 18 months, so the 2026 count is necessarily incomplete and should not be read as a drop-off.
Two views of the same 691-record set: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filings rose from 14 in 2017 to a peak of 19 in 2021, then held near that level (18 at the 2022 midpoint) without a further breakout. That pattern is consistent with a process technology where the core routes are settled and filing now clusters around incremental catalyst and purification improvements rather than new process architectures.
C07D (heterocyclic compounds, covering the lactam ring chemistry) appears in 73.7% of the 691 records, and B01J (catalysis and chemical/physical processes) in 37.0% — together they anchor the oxime-to-lactam conversion and the titanosilicate-catalysed ammoximation step. C07C (acyclic/carbocyclic compounds, 32.0%) and C07B (general organic methods, 16.2%) follow. Separation processes (B01D, 2.7%) and nitrogen-compound byproduct handling (C01C, 1.7%) are the thinnest classes, which is notable given how central the ammonium sulfate byproduct problem is to process economics.
Shares are the percentage of the 691 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about caprolactam and nylon 6 intermediate production and every answer comes back with the patent numbers behind it.
Try EurekaThe filing describes producing cyclohexanone oxime by ammoximation of cyclohexanone with hydrogen peroxide and ammonia over a titanosilicate catalyst, using a silicon-compound solid that had previously served as a Beckmann rearrangement catalyst. The stated aim is stable long-term oxime production rather than a one-off yield improvement.Assignee: Sumitomo Chemical. Filed 2012-03-29.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | CN1269360A | ε-己内酰胺的生产方法 | 59 |
| 2 | CN1332158A | ε-己内酰胺的制备方法 | 54 |
| 3 | CN1263091A | ε-己内酰胺的制备方法 | 53 |
| 4 | JP1990275850A | Production of epsilon-caprolactam | 50 |
| 5 | CN102050464A | 硅分子筛的合成方法 | 47 |
| 6 | CN1600428A | 一种含MFI结构分子筛催化剂的制备方法 | 42 |
| 7 | JP2000229939A | Production of epsilon-caprolactam | 39 |
| 8 | US6265574B1 | Process for producing epsi-caprolactam | 35 |
| 9 | JP2001072658A | Production of amide compound | 34 |
| 10 | US6828459B2 | Method for producing cyclohexanone oxime | 32 |
Citation counts favour older records simply by virtue of having had longer to accumulate them — read this as a map of influential prior art, not of current filing activity.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three read-outs from the concentration, geography and citation data that matter more than the raw counts.
With the five most active assignees holding 398 of 691 records and the next five bringing the total to 519, a new entrant filing a broad ammoximation or Beckmann rearrangement process claim is filing into ground already covered by incumbents. Differentiation now has to come from a specific catalyst formulation, byproduct handling step, or purity specification rather than the reaction sequence itself.
China leads receiving offices with 154 filings, ahead of the EPO at 103 and the US at 96, with Japan at 88, India at 44 and WIPO/PCT filings at 32. That ordering reflects where caprolactam production capacity and nylon 6 fibre manufacturing are concentrated, and it is a reasonable guide to where freedom-to-operate checks matter most.
The highest-cited records in this set date to the earlier caprolactam production era and describe core epsilon-caprolactam manufacturing methods; a molecular sieve synthesis patent also ranks highly, reflecting the catalyst work that underpins ammoximation. High citation counts here signal foundational influence within the searched corpus, not that these are the most relevant filings for a 2026 process design.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to caprolactam and nylon 6 intermediate production, with the prior art for and against each one.
The ranked leaders account for three-quarters of all filings between them; beyond that the field opens into a long tail of single- and low-digit filers.
The top-ranked assignee holds 206 of the 691 records in scope, roughly five times the fifth-place count of 39 and well ahead of the tenth-place count of 16. That gap between first and fifth place is the clearest sign of an incumbent with sustained, multi-generation process patenting rather than a single landmark filing.
Every one of the assignees with recent-year momentum data — including the field's largest filers — shows zero filings in the latest year. Given the 18-month publication lag this understates true 2026 activity, but it is also consistent with the flat filing trend since 2021: this looks like a period of consolidation around existing claims rather than new filing pushes.
Only 10 co-assignee pairs appear in the dataset. The strongest link, 31 shared records, sits between a major Chinese petrochemical group and its own research institute — an internal R&D-to-parent relationship rather than an external partnership. A second pairing at 15 shared records connects an industrial conglomerate with a university research group, suggesting academic collaboration plays a small but real role in catalyst-side innovation.
| Assignee | Recent year | YoY |
|---|---|---|
| Sumitomo Chemical Co., Ltd. | 0 | — |
| DSM IP Assets B.V. | 0 | — |
| China Petroleum & Chemical Corporation (Sinopec) | 0 | — |
| Mitsubishi Chemical Corporation | 0 | — |
| BASF SE | 0 | — |
| Sumitomo Chemical Industry Co., Ltd. | 0 | — |
| Sinopec Research Institute of Petroleum Processing | 0 | — |
| Honeywell International Inc. | 0 | — |
The landscape points to where claim space is occupied and where it is not — the next step is testing a specific process or claim against it.
If a project centres on ammoximation catalyst chemistry or a Beckmann rearrangement variant, run the specific catalyst formulation or process step against the leading assignees' portfolios before committing to a process design.
Explore this topic in Eureka →The thinner classes around byproduct handling and separation are promising but need validation against the full claim text, not just IPC counts, before a first claim is drafted.
Run a white space search in Eureka →The ammoximation route produces cyclohexanone oxime directly from cyclohexanone using hydrogen peroxide and ammonia over a titanosilicate catalyst, in a single step. The older hydroxylamine route requires a separately manufactured hydroxylamine intermediate, which adds process steps and byproduct streams. This dataset shows ammoximation-related claims sitting inside the dominant C07D and B01J classes, reflecting its status as the more heavily patented modern route, while hydroxylamine-route filings are a smaller, older slice of the same corpus.
The classical Beckmann rearrangement and older oxime-production routes generate large volumes of ammonium sulfate as a low-value byproduct, and its disposal or valorisation has a direct effect on process economics. Despite that centrality, byproduct-handling classes such as C01C (ammonia, cyanides and nitrogen compounds) account for only 1.7% of the 691 records in scope, which is thin relative to the core reaction chemistry. That gap is one of the clearer under-claimed branches in this landscape.
Filing in this space is concentrated: the five most active assignees together account for 398 of 691 records (57.6%), and the ten most active account for 519 (75.1%). The leading assignee alone holds 206 records, several times the count of the fifth-place holder at 39. Major chemical producers with long-running caprolactam and nylon 6 operations dominate the ranking, alongside dedicated research institutes affiliated with large petrochemical groups.
The filing trend suggests maturity rather than growth: annual filings rose from 14 in 2017 to a peak of 19 in 2021, then held around 18 by the 2022 midpoint without further increase. Recent-year momentum data shows even the largest assignees recording zero filings in the latest year, though the roughly 18-month publication lag means the most recent year understates true activity. Taken together, this looks like a settled technology space where innovation is incremental rather than a rapidly expanding one.
The thinnest IPC classes relative to the core chemistry are separation processes (B01D, 2.7% of records) and nitrogen-compound handling (C01C, 1.7%), both of which sit downstream of the main reaction steps rather than inside them. Mixing and reactor design (B01F, 5.1%) is similarly under-represented given how sensitive ammoximation yield is to reactor conditions. These branches are candidates for narrowly scoped claims, but any claim there should be checked against the specific process language of existing filings, not just against IPC class counts.
Go past this page: query the whole caprolactam and nylon 6 intermediate production corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.